Excelsior Biopharma (6496) — Cash Flow Reinvestment Rate
Excelsior Biopharma (6496) has a Cash Flow Reinvestment Rate of 6.86x as of June 2025, reinvesting NT$26.07 Million (capex NT$14.44 Million plus investments NT$-11.63 Million) from operating cash flow of NT$3.80 Million. Explore reinvestment intensity of Excelsior Biopharma to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Excelsior Biopharma Cash Flow Reinvestment Rate (2017–2022)
Historical reinvestment intensity for Excelsior Biopharma across 5 annual periods. Also explore Excelsior Biopharma total assets for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Excelsior Biopharma (2017–2022)
Year-by-year capital reinvestment analysis for Excelsior Biopharma. For live market cap and broader valuation context, see Excelsior Biopharma stock valuation.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 37.88x | NT$207.78 Million | NT$5.49 Million | NT$7.78 Million | ▲ +23704.4% |
| 2021 | 0.16x | NT$8.88 Million | NT$55.82 Million | NT$2.88 Million | ▲ +89.2% |
| 2020 | 0.08x | NT$43.80 Million | NT$520.81 Million | NT$11.62 Million | ▼ -74.3% |
| 2018 | 0.33x | NT$41.51 Million | NT$126.92 Million | NT$9.54 Million | ▲ +524.0% |
| 2017 | 0.05x | NT$18.32 Million | NT$349.47 Million | NT$18.10 Million | — |